ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma announced positive clinical updates for its core assets, olverembatinib and lisaftoclax, at the 31st European Hematology Association (EHA2026) Congress. Olverembatinib showed deep and durable responses in CML and robust clinical response in Ph+ ALL, including a 94.4% CR/CRi rate in newly diagnosed Ph+ ALL. Lisaftoclax demonstrated promising efficacy in myeloid neoplasms with a 72% CR/CRi rate in AML and clinical activity in R/R CLL/SLL with a median PFS of 23.9 months. The data validates the therapeutic value and potential of these therapies.

Ascentage Pharma presented positive clinical data for two key assets, alrizomadlin and olverembatinib, at ASCO 2026. Alrizomadlin showed preliminary antitumor activity and a manageable safety profile in pediatric solid tumors, including a complete response in rhabdomyosarcoma and 23.5% ORR in combination. Updated data for olverembatinib as a second-line CML-CP therapy demonstrated deepening responses (91.3% CCyR, 60.9% MMR at cycle 24) and a manageable safety profile. Additionally, olverembatinib combined with blinatumomab showed encouraging activity in CML-LBP and Ph+ BCP-ALL, with 91% CR/CRi and high MRD negativity rates in international patients.

Ascentage Pharma announced positive results from a Phase Ib study of olverembatinib in combination with blinatumomab for lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL). The data, presented at the 2026 ASCO Annual Meeting, showed encouraging clinical activity with strong response rates and minimal residual disease (MRD) clearance in international patients. The combination regimen was generally well tolerated, consistent with individual agent toxicities, highlighting its potential as a novel, chemotherapy-free strategy.

Ascentage Pharma presented its first dataset of alrizomadlin (APG-115) as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma or other soft-tissue sarcomas at the ASCO Annual Meeting. The data demonstrated preliminary antitumor activity and a manageable tolerability profile, including one complete response with monotherapy and an objective response rate of 23.5% in the combination arm. Alrizomadlin has also been included in China's "SPARK Plan" for pediatric solid tumors, highlighting its potential as a first-in-class therapy.

Ascentage Pharma announced updated efficacy and safety data for its first approved product, olverembatinib, as a second-line therapy for chronic-phase chronic myeloid leukemia (CML-CP) at the 2026 ASCO Annual Meeting. The data showed a complete cytogenetic response (CCyR) rate of 91.3% and a major molecular response (MMR) rate of 60.9% at cycle 24, with responses deepening over time. Olverembatinib demonstrated a stable and manageable safety profile, further supporting its potential as a second-line treatment option. The company is also conducting three global registrational Phase III studies for olverembatinib and has an exclusive option agreement with Takeda for global rights outside certain territories.

Ascentage Pharma Group International announced that its Trustee purchased 100,000 existing shares on-market on May 27, 2026. These shares were acquired for the purpose of the 2022 RSU Scheme to satisfy Restricted Share Units upon vesting. The total consideration for this purchase was HK$3,977,000, at an average price of approximately HK$39.77 per share. Following this transaction, the Trustee now holds a total of 2,265,000 shares for the scheme.

Ascentage Pharma announced the release of latest clinical data from multiple trials at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Six abstracts were selected for presentation, including three rapid oral presentations, showcasing data from lead drug candidates olverembatinib, lisaftoclax, and alrizomadlin with positive efficacy and safety profiles. Additionally, the company's Annual General Meeting (AGM) on May 20, 2026, saw all proposed resolutions passed, including the re-election of directors, re-appointment of auditors, and approval of general mandates for share allotment and repurchase.

Ascentage Pharma announced that six abstracts from its clinical studies, featuring three lead drug candidates (olverembatinib, lisaftoclax, and alrizomadlin), have been selected for presentation at the 2026 ASCO Annual Meeting. Three studies will be rapid oral presentations and three will be poster presentations. The abstracts report positive efficacy and safety data from ongoing studies, including high response rates for olverembatinib in CML and preliminary antitumor activity for alrizomadlin alone or in combination with lisaftoclax in pediatric sarcomas. Updates on two global Phase 3 registrational studies (POLARIS-2 for olverembatinib and GLORA for lisaftoclax) will also be presented.

Ascentage Pharma Group International announced that 17 clinical advances of its core assets, Olverembatinib and Lisaftoclax, will be featured at the 31st Congress of the European Hematology Association (EHA2026). These include 8 poster presentations showcasing updated efficacy and safety data from ongoing clinical studies. The EHA2026 Congress is scheduled to convene in Stockholm, Sweden, from June 11 to 14, 2026.

Ascentage Pharma Group International announced that its management is scheduled to participate in three upcoming investor conferences. These engagements include one-on-one meetings at the B. Riley Commercial/Late-Stage Oncology Best Ideas Summit on May 18, and at the Stifel 2026 Virtual Targeted Oncology Forum on May 19, which will also feature a fireside chat. Additionally, the company will hold one-on-one meetings and deliver a presentation at the Jefferies Global Healthcare Conference on June 3. Webcasts for the fireside chat and presentation will be accessible via the company's investor relations website.